Financial analysis of Biotricity (BTCY) compared to its peers


Biotricity (OTCMKTS:BTCY – Get Rating) is one of 85 public companies in the “electrical services” sector, but how does it stack up against its rivals? We will compare Biotricity to related companies based on its risk strength, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares the net margins, return on equity and return on assets of Biotricity and its competitors.

Net margins Return on equity return on assets
Biotricity N / A N / A N / A
Biotricity Competitors -8.03% 7.30% 2.22%

Insider and Institutional Ownership

5.5% of Biotricity shares are held by institutional investors. In comparison, 66.9% of the shares of all “Electrical Services” companies are held by institutional investors. 2.4% of the shares of all “Electrical Services” companies are held by insiders of the company. Strong institutional ownership indicates that large money managers, endowments, and hedge funds believe a company is poised for long-term growth.

Valuation and benefits

This chart compares the revenue, earnings per share (EPS), and valuation of Biotricity and its rivals.

Gross revenue Net revenue Price/earnings ratio
Biotricity $7.70 million N / A -2.00
Biotricity Competitors $9.22 billion $453.34 million 4:60 p.m.

Biotricity’s competitors have higher revenues and profits than Biotricity. Biotricity trades at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Biotricity has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, Biotricity’s competitors have a beta of -1.19, suggesting that their average stock price is 219% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biotricity and its rivals, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Biotricity 0 1 2 0 2.67
Biotricity Competitors 544 3285 3091 59 2.38

Biotricity currently has a consensus price target of $5.67, indicating a potential upside of 316.67%. As a group, the “electrical services” companies have an upside potential of 11.60%. Given Biotricity’s stronger consensus rating and higher likely upside, equity research analysts clearly believe that Biotricity is more favorable than its rivals.

Summary

Biotricity’s rivals beat Biotricity on 7 of the 12 factors compared.

Biotricity Company Profile

(Get a rating)

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The Company is focused on providing remote monitoring solutions to the medical, healthcare and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic disease. It offers the Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and a software solution. The company is based in Redwood City, California.



Get news and reviews for Biotricity Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotricity and related companies with MarketBeat.com’s FREE daily newsletter.


Source link

Comments are closed.